story of the week
Safety and Immunogenicity of Heterologous vs Homologous Prime-Boost Schedules With an Adenoviral-Vectored and mRNA COVID-19 Vaccine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Immunogenicity of Heterologous Versus Homologous Prime-Boost Schedules With an Adenoviral Vectored and mRNA COVID-19 Vaccine (Com-COV): A Single-Blind, Randomised, Non-Inferiority Trial
Lancet 2021 Aug 06;[EPub Ahead of Print], X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, JC Cameron, S Charlton, EA Clutterbuck, AM Collins, T Dinesh, A England, SN Faust, DM Ferreira, A Finn, CA Green, B Hallis, PT Heath, H Hill, T Lambe, R Lazarus, V Libri, F Long, YF Mujadidi, EL Plested, S Provstgaard-Morys, MN Ramasamy, M Ramsay, RC Read, H Robinson, N Singh, DPJ Turner, PJ Turner, LL Walker, R White, JS Nguyen-Van-Tam, MD SnapeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.